Biotech Updates: Eli Lilly's Spending and Humira's Market Dominance

Eli Lilly has increased its expenditures on GLP-1 medications, reflecting its commitment to this growing sector of the biotech market.

Humira remains a significant case study in the realm of monopolistic practices within the pharmaceutical industry, showcasing the complexities of market control.

These updates highlight ongoing trends and developments in biotechnology, underscoring the importance of staying informed in this rapidly evolving field.